Abstract
Background
The phenotyping of individuals using robust tools as lipidomics is crucial to implement preventive personalised medicine. Combining the findings from multiomics can result in broader CV risk-capturing, uncovering relevant molecules in highly prevalent syndromes conditions such as the Cardiovascular-Kidney-Metabolic (CKM).
Purpose
To discern the lipid metabolites with predictive power for the correct identification of patients at CKM Stage 4 and those who required advanced revascularization interventions, coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI).
Methods
Participants scheduled for a coronary angiogram in the CARDINOX agreed to provide blood. PBMCs were isolated for flow cytometry and plasma samples were processed for immunoassay and targeted lipidomics using liquid chromatography–mass spectrometry, spanning 1143 lipids from 20 different classes. Patients were assigned to stages using the AHA CKM definition. Statistical analyses were performed in R and GraphPad prism, using the LipidR package for analysis and multiple logistic regression for biomarker performance estimation.
Results
200 subjects were recruited, median age 67 years (IQR 58-74), 21% female, 42.5% had obesity, 42% had diabetes and 31% presented with an acute coronary syndrome (ACS). 39% were at CKM-Stage 3 and 20% at CKM-Stage 4; 31.5% required PCI and 13% of patients required CABG. The best predictive model for CKM-Stage 4 included NOX5 in PBMCs, Monocytes and plasma, two lysophosphatidylcholines (LPC) 18:1, LPC 20:0 and two phosphatidylcholines (PC) 14:0/18:2, PC 18:2/18:2, AUC=0.90, p<0.0001, NPV=91.0%, PPV=85.2%. The best model for those needing PCI included NOX5 in PBMCs and Monocytes, and five lipids: phosphatidylinositol (PI) 20:0/18:1, TG 54:3/16:0, TG 56:6/20:3, PC 18:1/18:3, and the diacylglycerol (DG) 16:0/20:5, AUC=0.92, p<0.0001, NPV=88.3%, PPV=85%. In the case of CABG, the best model included NOX5 in Monocytes and PBMCs, PC 18:1/18:3, PC 16:1/18:2, two triacylglycerols (TG) 54:3/16:0, TG 56:6/20:3 and the PI 18:0/20:3, AUC=0.96, p<0.0001, NPV=96.7%, PPV=90.9%. These models outperformed the predictive power of considering only the clinical or lipid parameters and achieved perfect discrimination when routine clinical variables were added.
Conclusions
Using a targeted lipidomic approach can substantially improve the classification of patients at advanced CV risk. When combining a few of the most differentially expressed lipids with other novel biomarkers such as NOX5, we obtained a clear distinction of patients that presented with CKM Stage 4 and those who required advanced revascularization (PCI and CABG). Additionally, these lipids hold the potential to inform biologically relevant pathways in CVD. When validated in prospective and external populations, NOX5 and lipidomic panels can be easily translated to the clinic for earlier identification of individuals at risk of adverse coronary outcomes.
[Table Omitted]